Repligen SecreFlo sNDA approval
This article was originally published in Pharmaceutical Approvals Monthly
Repligen gains approval Nov. 1 to expand indications for SecreFlo (secretin) to include stimulation of pancreatic secretions to facilitate identification and cannulation of pancreatic ducts in patients undergoing endoscopic retrograde cholangio-pancreatography (ERCP). A randomized, placebo controlled crossover study in 31 patients undergoing ERCP resulted in 25 of 28 successful cannulations of the minor duct for SecreFlo compared to 1 of 16 for placebo, labeling notes. SecreFlo previously was approved for stimulation of pancreatic secretions to aid in the diagnosis of pancreatic exocrine dysfunction and for stimulation of gastrin secretion to aid in the diagnosis of gastrinom
You may also be interested in...
To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.
President Biden’s picks to fill two commissioner posts may shift dynamics on pharmaceutical industry enforcement. Rohit Chopra’s nomination to Consumer Financial Protection Bureau removes strong critic of pharma mergers.